PMID- 33844022
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210709
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 60
IP  - 5
DP  - 2021 May 14
TI  - Comparative effectiveness of guselkumab in psoriatic arthritis: results from 
      systematic literature review and network meta-analysis.
PG  - 2109-2121
LID - 10.1093/rheumatology/keab119 [doi]
AB  - OBJECTIVE: The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab 
      for psoriatic arthritis (PsA) has recently been demonstrated in two phase 3 
      trials (DISCOVER-1 & -2) but has not been evaluated vs other targeted therapies 
      for PsA. The objective was to compare guselkumab to targeted therapies for PsA 
      for safety and joint and skin efficacy through network meta-analysis (NMA). 
      METHODS: A systematic literature review was conducted in January 2020 to identify 
      randomized controlled trials. Bayesian NMAs were performed to compare treatments 
      on American College of Rheumatology (ACR) 20/50/70 response, mean change from 
      baseline in van der Heijde-Sharp (vdH-S) score, Psoriasis Area Severity Index 
      (PASI) 75/90/100 response, adverse events (AEs) and serious adverse events 
      (SAEs). RESULTS: Twenty-six phase 3 studies evaluating 13 targeted therapies for 
      PsA were included. For ACR 20 response, guselkumab 100 mg every 8 weeks (Q8W) was 
      comparable to IL-17A inhibitors and subcutaneous tumor necrosis factor (TNF) 
      inhibitors. Similar findings were observed for ACR 50 and 70. For vdH-S score, 
      guselkumab Q8W was comparable to other agents except intravenous TNF therapies. 
      Results for PASI 75 and PASI 90 response suggested guselkumab Q8W was better than 
      most other agents. For PASI 100, guselkumab Q8W was comparable to other active 
      agents. For AEs and SAEs, guselkumab Q8W ranked highly but comparative 
      conclusions were uncertain. Similar results were observed for all outcomes for 
      guselkumab 100 mg every four weeks. CONCLUSIONS: In this NMA, guselkumab 
      demonstrated favorable arthritis efficacy comparable to IL-17A and subcutaneous 
      TNF inhibitors while offering better PASI response relative to many other 
      treatments.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology.
FAU - Mease, Philip J
AU  - Mease PJ
AUID- ORCID: 0000-0002-6620-0457
AD  - Swedish Medical Center/Providence St. Joseph Health & University of Washington, 
      Seattle, WA, USA.
FAU - McInnes, Iain B
AU  - McInnes IB
AD  - University of Glasgow, Centre for Rheumatic Diseases, United Kingdom.
FAU - Tam, Lai-Shan
AU  - Tam LS
AUID- ORCID: 0000-0001-6410-8852
AD  - The Chinese University of Hong Kong and The Prince of Wales Hospital, Department 
      of Medicine & Therapeutics, Hong Kong.
FAU - Eaton, Kiefer
AU  - Eaton K
AUID- ORCID: 0000-0002-4369-233X
AD  - EVERSANA, Marketing and Market Access, Burlington, Ontario, Canada.
FAU - Peterson, Steve
AU  - Peterson S
AD  - Janssen Global Services LLC, Immunology, Global Commercial Strategy Organization, 
      Horsham, PA, USA.
FAU - Schubert, Agata
AU  - Schubert A
AD  - Janssen-Cilag Ltd, Dermatology and Rheumatology, Warsaw, Poland.
FAU - Chakravarty, Soumya D
AU  - Chakravarty SD
AUID- ORCID: 0000-0001-7957-838X
AD  - Janssen Scientific Affairs LLC, Immunology, Horsham.
AD  - Drexel University College of Medicine, Philadelphia, PA, USA.
FAU - Parackal, Anna
AU  - Parackal A
AD  - EVERSANA, Marketing and Market Access, Burlington, Ontario, Canada.
FAU - Karyekar, Chetan S
AU  - Karyekar CS
AD  - Janssen Global Services LLC, Immunology, Global Commercial Strategy Organization, 
      Horsham, PA, USA.
FAU - Nair, Sandhya
AU  - Nair S
AD  - Janssen Pharmaceutical NV, Health Economics Design and Analytics, Beerse, 
      Belgium.
FAU - Boehncke, Wolf-Henning
AU  - Boehncke WH
AD  - Geneva University Hospitals, Department of Medicine, Geneva, Switzerland.
FAU - Ritchlin, Christopher
AU  - Ritchlin C
AD  - University of Rochester, Department of Medicine, Rochester, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 089658A12D (guselkumab)
SB  - IM
CIN - Rheumatology (Oxford). 2021 Jul 1;60(7):3042-3044. PMID: 33792657
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy
MH  - Humans
MH  - Network Meta-Analysis
MH  - Treatment Outcome
PMC - PMC8121447
OTO - NOTNLM
OT  - ACR
OT  - NMA
OT  - PASI
OT  - SLR
OT  - TNF
OT  - biologics
OT  - guselkumab
OT  - interleukin
OT  - psoriatic arthritis
EDAT- 2021/04/13 06:00
MHDA- 2021/06/30 06:00
PMCR- 2021/05/14
CRDT- 2021/04/12 12:44
PHST- 2020/12/02 00:00 [received]
PHST- 2021/01/28 00:00 [revised]
PHST- 2021/01/30 00:00 [accepted]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2021/04/12 12:44 [entrez]
PHST- 2021/05/14 00:00 [pmc-release]
AID - 6222946 [pii]
AID - keab119 [pii]
AID - 10.1093/rheumatology/keab119 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2021 May 14;60(5):2109-2121. doi: 
      10.1093/rheumatology/keab119.